Rheumatology Department, Gülhane Training and Research Hospital, University of Health Sciences Turkey, 38000 Ankara, Turkey.
Medicina (Kaunas). 2024 Oct 22;60(11):1728. doi: 10.3390/medicina60111728.
: Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent febrile attacks and serosal inflammation. The goals of FMF treatment are to prevent acute attacks and the development of amyloidosis. This study aimed to investigate the benefit of switching to compressed colchicine tablets in patients with FMF who are resistant or intolerant to the pharmaceutical preparation of coated colchicine tablets in terms of attack frequency and side effects. : Patients who developed resistance and intolerance under coated colchicine tablet treatment and, therefore, switched to compressed colchicine tablets were identified. The attack frequencies and drug-related side effects in patients using the two different pharmaceutical colchicine preparations were compared. : The mean age of the 172 patients treated with compressed tablets alone following coated tablets was 36.3 ± 11.4 years, and 75 (43.6%) were male. The most common genetic mutation was detected as M694V in 111 (64.5%) patients, and 36 (20.9%) of them were homozygous. A decrease in the daily colchicine dose was found after switching to compressed colchicine tablets in patients followed for 7 years (2.1 ± 0.7 mg vs. 1.7 ± 0.5 mg; < 0.001). Episodes lasted for one to three days and then resolved spontaneously. After treatment with the compressed tablet form of colchicine, 129 (75%), 33 (19%), and 10 (6%) patients had 0-3, 4-6, and more than 7 attacks, respectively ( < 0.001). Diarrhea and aminotransferase elevation, the most common side effects in patients using coated colchicine tablets, decreased after using compressed colchicine tablets ( < 0.001). : Compressed colchicine tablets were shown to be effective in patients who did not respond to coated colchicine therapy and those with pre-treatment intolerance to biological agents.
家族性地中海热（FMF）是一种遗传性自身炎症性疾病，其特征为反复发作的发热性发作和浆膜炎。FMF 的治疗目标是预防急性发作和淀粉样变性的发生。本研究旨在探讨在对包衣秋水仙碱片治疗有抵抗或不耐受的 FMF 患者中，改用压缩秋水仙碱片治疗在发作频率和副作用方面的益处。
识别出在包衣秋水仙碱片治疗下出现抵抗和不耐受的患者，并比较了使用两种不同秋水仙碱制剂的患者的发作频率和与药物相关的副作用。
在 172 名单独使用压缩片剂治疗的患者中，平均年龄为 36.3±11.4 岁，75 名（43.6%）为男性。最常见的基因突变在 111 名（64.5%）患者中检测到为 M694V，其中 36 名（20.9%）为纯合子。在随访 7 年的患者中，发现从包衣秋水仙碱片切换到压缩秋水仙碱片后，每日秋水仙碱剂量减少（2.1±0.7mg 对 1.7±0.5mg；<0.001）。发作持续一至三天，然后自行缓解。使用秋水仙碱压缩片剂治疗后，129 名（75%）、33 名（19%）和 10 名（6%）患者的发作次数分别为 0-3、4-6 和>7 次（<0.001）。在使用包衣秋水仙碱片的患者中最常见的副作用腹泻和氨基转移酶升高在使用压缩秋水仙碱片后减少（<0.001）。
在对包衣秋水仙碱治疗无反应和对生物制剂治疗不耐受的患者中，压缩秋水仙碱片显示出有效性。
